Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

计划入组 875 人 · 首次发布于 2025 年 11 月 3 日

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

计划入组 171 人 · 首次发布于 2023 年 8 月 21 日

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

计划入组 32 人 · 首次发布于 2026 年 2 月 17 日

Acute Myeloid Leukemia(Advesya)

DCPS inhibitor (acute myeloid leukemia)

MYELOID THERAPEUTICS

United States

JAPAN ADULT LEUKEMIA STUDY GROUP

Japan

Bio-Path Holdings

United States

Kura Oncology's Ziftomenib Receives FDA Priority Review for NPM1-Mutant AML, PDUFA Date Set for November 2025

Ziftomenib Shows Promise in Pivotal KOMET-001 Trial for Relapsed/Refractory NPM1-Mutant AML

Kura Oncology's Menin Inhibitor Ziftomenib Receives FDA IND Clearance for Advanced GIST